TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukimia

• Main Authors: Zainuddin, Norafiza, Murray, Fiona, Kanduri, Meena, Gunnarsson, Rebeqa, E. Smedby, Karin, Enblad, Gunilla, Jurlander, Jesper, Juliusson, Gunnar, Rosenquist, Richard
• Format: Article
• Language: English
• Published: Pergamon 2011
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://irep.iium.edu.my/4434/1/p53_CLL.pdf; http://irep.iium.edu.my/4434/; http://www.sciencedirect.com/science/article/pii/S0145212610004285

TP53 mutations in the absence of 17p-deletion correlate with rapid disease progression and poor survival in chronic lymphocytic leukemia (CLL). Herein, we determined the TP53 mutation frequency in 268 newly diagnosed CLL patients from a population-based material. Overall, we detected TP53 mutations in 3.7% of patients (n = 10), where 7/10 cases showed a concomitant 17p-deletion, confirming the high prevalence of TP53 mutation in 17p-deleted patients. Only 3 (1.1%) of the newly diagnosed patients in our cohort thereby carried TP53 mutations without 17p-deletion, a frequency that is much lower than previous reports on referral cohorts (3–6%). Our findings imply that TP53 mutations are rare at CLL onset and instead may arise during disease progression.